Core Viewpoint - The company has entered into a strategic cooperation framework agreement with Huada Co-Win to establish an innovative drug intellectual property tokenization fund, aiming to enhance its business layout and role in reshaping the global medical innovation drug asset value chain [1][2] Group 1 - The company will collaborate with Huada Co-Win to create the IVD-BGICoWin fund, which will invest in projects under the NewCo+RWA Web3 exchange ecosystem [1] - The company or its designated entities will act as limited partners contributing to the fund, while Huada Co-Win will serve as the general partner responsible for managing the fund [1] - Huada Co-Win is a private equity fund management company with extensive experience and resources in the innovative medical and pharmaceutical sectors [1] Group 2 - The board believes that this strategic cooperation will advance the company's three-pronged strategy of "NewCo+RWA+stablecoin" to expand its business [2] - The board considers the framework agreement to be in the overall interest of the company and its shareholders [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 自願性公告 與華大共贏的戰略合作 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 自 願 作 出，旨 在 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 本 集 團 最 近 發 展 的 最 新 資 料。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，於 二 零 二 五 年 七 月 三 十 日，本 公 司 與 華 大 共 贏（深 圳）股 權 投 資 基 金 管 理 有 限 公 司（「華大共贏」）訂 立 戰 略 合 作 框 架 協 議（「框 架協議」），共 同 建 立 華 檢 華 大 共 贏 創 新 藥 知 識 產 權 代 幣 化 基 ...

IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 自願性公告 「IVD」品 牌slogan煥 新、更 換 企 業 標 誌（新LOGO）暨 新官方網站上線 本 公 告 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或（「華檢醫療」），連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 本 公 司 股 東（「股 東」）及 潛 在 投 資 者 披 露 本 集 團 品 牌 形 象 升 級 及 數 字 化 入 口 煥 新 的 最 新 進 展。 一、戰略背景與升級要點 為配合本集團於2025年7月17日 及20日 公 告 的「NewCo+RWA」Web3交易所生 態 戰 略（IVDNewCo Exchange及IVDD穩 定 幣 計 劃），彰 顯 向「全 球 醫 療 創 新 價 值 鏈－去 中 心 化 科 學 生 態 構 建 者」的 戰 略 轉 型，董 事 會 欣 然 宣 佈 以 下 重 大 品 牌 升 級 舉 措： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 ...

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase of over 16% following the announcement of a successful multi-billion yuan revolving loan obtained by its subsidiary, Weishida, from a banking syndicate led by East Asia Bank's Shanghai branch [1] Group 1: Financial Developments - The revolving loan involves participation from seven financial institutions, including Mitsui Sumitomo, Shengjing Bank, and Busan Bank of Korea [1] - The stock price rose by 16.31%, reaching HKD 4.35, with a trading volume of HKD 15.16 million [1] Group 2: Strategic Initiatives - On July 17, the company announced the establishment of the "IVDNewCo Exchange," a Web3 ecosystem focused on high-tech medical innovation assets, along with the issuance of a proprietary stablecoin, IVD Dollar (IVDD) [1] - On July 20, Huajian Medical registered a wholly-owned subsidiary, IVD GROUP INC., in New York, and initiated the application for stablecoin licenses with the SEC and CFTC [1] Group 3: Market Positioning - The "IVDNewCo Exchange" aims to address significant pain points in the pharmaceutical industry, where new drug development typically takes 10 years and 80% of funding is spent in clinical stages, while ordinary investors are often excluded [1] - The company’s strategy involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates through RWA technology [1] - Huajian Medical aims to become the "Nasdaq + Uniswap" of the medical RWA sector, ensuring compliance while achieving decentralized liquidity, leveraging its first-mover advantage in a niche market [1]

智通财经APP获悉，华检医疗(01931)尾盘涨超16%，截至发稿，涨16.31%，报4.35港元，成交额1516.12 万港元。 消息面上，7月29日，华检医疗发布公告称，子公司威士达成功获得一笔数亿元循环贷款。该银团贷款 由东亚银行上海分行牵头，三井住友、盛京银行、韩国釜山银行等7家金融机构组成的银团共同参与。 值得注意的是，7月17日，公司宣布构建全球首个聚焦医疗创新药高科技资产的"NewCo+RWA"Web3交 易所生态，命名为"IVDNewCo Exchange"，并配套发行专有稳定币IVD Dollar（IVDD）；7月20日，华 检医疗在美国纽约注册成立全资子公司IVD GROUP INC.，同步启动向SEC、CFTC提交稳定币牌照申请 智通财经APP在《稳定币条例生效前夜 华检医疗(01931)收获三张实际"信任票"》中指出，公司构建名 为"IVDNewCo Exchange"的Web3交易所生态，直击医药行业痛点：一款新药研发需10年，80%资金砸 在临床阶段，普通投资者却被拒之门外。华检医疗的解决方案是将高价值医疗资产——如Ⅱ期临床的 ADC药物、基因疗法专利——通过RWA技术转化为可分割 ...

7月29日，华检医疗(01931)发布公告——子公司威士达成功获得一笔数亿元循环贷款。这笔由东亚银行上海分行牵头，三井住友、盛京银行、韩国釜山银行 等7家金融机构组成的银团共同参与的贷款，在当下信贷紧缩的环境下显得格外珍贵。贷款获批不仅是对子公司经营能力的认可，更是国际资本对华检医疗 未来战略的押注。 一、监管破冰：全球稳定币合规竞赛鸣枪起跑 8月1日，香港《稳定币条例》即将生效。这标志着全球三大金融中心全部完成稳定币立法布局：欧盟MiCA法案去年底生效，美国《天才法案》7月18日由 特朗普签署。监管铁幕落下，野蛮生长时代终结，合规竞赛正式鸣枪。 香港金管局对此态度鲜明。助理总裁何汉杰直言："先严、走稳，再适度放松。"监管层对牌照发放极为谨慎，首批仅计划发放"极少数"牌照。数十家跃跃欲 试的机构中，仅渣打、京东旗下JD Coinlink等沙盒参与者或获优先审核——但"优先权不保证获批"。 华检医疗7月30日公告 时间点耐人寻味。就在两天后的8月1日，香港《稳定币条例》将正式生效。而在过去半个月，华检医疗股价经历了一场过山车：7月14日至21日累计暴涨 75%，创下4.66港元历史新高;7月23日—28日，公司 ...

Core Viewpoint - Huajian Medical has successfully secured a multi-billion yuan revolving loan for its subsidiary, demonstrating recognition of its operational capabilities and international capital's confidence in its future strategy [1] Group 1: Loan Acquisition - The loan was led by East Asia Bank's Shanghai branch, with participation from seven financial institutions, highlighting its significance in a tightening credit environment [1] - The loan approval is seen as a vote of confidence in Huajian Medical's development blueprint [22] Group 2: Stock Market Activity - Huajian Medical's stock price surged by 75% from July 14 to July 21, reaching a historical high of 4.66 HKD [5][15] - The company executed three high-priced stock buybacks from July 23 to July 28, spending over 6.13 million HKD, indicating management's confidence in the company's future [17][22] Group 3: Regulatory Environment - The Hong Kong Stablecoin Regulation will take effect on August 1, marking a significant regulatory shift in the global financial landscape [6] - The Hong Kong Monetary Authority (HKMA) has set high standards for stablecoin issuance, with only a few licenses expected to be granted initially [6][7] Group 4: Strategic Initiatives - Huajian Medical announced plans to establish a Web3 exchange focused on medical innovation assets and to issue a corresponding stablecoin, IVDD [8][9] - The company is pursuing stablecoin licenses in both the U.S. and Hong Kong, aiming to become the first medical technology firm to obtain such licenses in both markets [14] Group 5: Market Potential - The global market for Real World Asset (RWA) tokenization is projected to grow significantly, with estimates reaching 16.1 trillion USD by 2030 [24] - The stablecoin market is also expanding rapidly, with a total market cap of 263.6 billion USD, surpassing traditional payment systems [25] Group 6: Future Outlook - Huajian Medical's dual strategy of compliance in Hong Kong and aggressive expansion in the U.S. positions it uniquely in the market [26] - The company's innovative approach could potentially lead to a significant increase in market capitalization, with the possibility of reaching a valuation in the hundreds of billions [25][26]

Group 1 - The core viewpoint of the article highlights the strategic moves by Huajian Medical, including the successful fundraising of a multi-billion RMB sustainable development-linked revolving loan and the launch of a Web3 exchange ecosystem for medical innovation drugs [1][2][3] - The revolving loan, led by East Asia Bank and supported by several international financial institutions, provides Huajian Medical with a flexible and ample medium to long-term funding pool, enhancing its capital structure and enabling it to seize industry growth opportunities [2][3] - Huajian Medical's stock price surged by 75% from July 14 to July 21, reaching a historical peak of 4.66 HKD, reflecting strong market sentiment and confidence in the company's future prospects [1][3] Group 2 - The management's decision to repurchase shares at high prices, following the stock's peak, signals confidence in the company's strategic direction and future growth [4][5] - The company has initiated a plan to establish a Web3 exchange named "IVDNewCo Exchange," which aims to integrate medical innovation drug assets with blockchain technology, potentially revolutionizing traditional pharmaceutical financing [5][6] - The proposed ecosystem includes a tokenization platform for real-world assets (RWA), a decentralized exchange for 24/7 global trading, and a stablecoin (IVDD) for transactions within the ecosystem [6][8] Group 3 - The global RWA market is projected to grow significantly, reaching 16.1 trillion USD by 2030, indicating a favorable environment for Huajian Medical's tokenization strategy [8][9] - The stablecoin market is also expanding, with a total market cap of 263.6 billion USD, suggesting a growing acceptance of new financial infrastructures [8][9] - Regulatory developments, such as the upcoming Hong Kong Stablecoin Regulation, are expected to facilitate Huajian Medical's initiatives in the Web3 space, enhancing investor confidence [8][9]

Group 1 - The core viewpoint of the news is that Huajian Medical has successfully raised a multi-billion RMB sustainable development-linked revolving syndicated loan, which reflects the confidence of financial institutions in the company's future prospects and strategic initiatives [1][2][3] - The loan, led by East Asia Bank (China) and involving several international and regional financial institutions, provides Huajian Medical with a flexible and ample medium to long-term funding pool, enhancing its capital structure and enabling it to seize industry growth opportunities [2] - The company's stock price surged by 75% from July 14 to July 21, reaching a historical peak of 4.66 HKD, indicating strong market sentiment and investor confidence in its strategic direction [1][3] Group 2 - Huajian Medical's management demonstrated confidence by repurchasing shares at high prices after the stock reached historical highs, signaling their belief in the company's strategic future [4] - The company executed multiple stock buybacks between July 23 and July 28, spending over 6.13 million HKD, which reflects a strong endorsement of its "Web3 + innovative drug" strategy [4] - The establishment of a wholly-owned subsidiary in the U.S. and the initiation of stablecoin license applications further support the company's strategic ambitions [4] Group 3 - Huajian Medical aims to revolutionize the medical asset landscape by creating the "IVDNewCo Exchange," a Web3 ecosystem that integrates innovative drug assets with blockchain technology [5][6] - The proposed ecosystem includes a tokenization platform for real-world assets (RWA), a decentralized exchange for 24/7 global trading, and the IVDD stablecoin as a universal payment medium [6] - The strategy addresses the traditional pharmaceutical development model's pain points, allowing early-stage investors to share in the success of clinical trials through tokenized assets [6] Group 4 - The global RWA market is projected to grow significantly, reaching 16.1 trillion USD by 2030, indicating a favorable environment for Huajian Medical's tokenization strategy [8] - The stablecoin market is also expanding, with a total market cap of 263.6 billion USD, highlighting the potential for new financial infrastructure [8] - Regulatory developments, such as the upcoming Hong Kong Stablecoin Regulation, are expected to facilitate Huajian Medical's initiatives in the crypto-financial space [8] Group 5 - The market's response to Huajian Medical's initiatives is mixed, with strong stock performance indicating investor willingness to pay a premium for the "Web3 + innovative drug" narrative, while also reflecting concerns about the volatility and speculative nature of the market [9] - If successful, Huajian Medical's Web3 ecosystem could open new financing channels for medical assets, reducing investment barriers and enhancing liquidity in the traditionally closed innovative drug development space [9] - The combination of the syndicated loan, rising stock prices, and share buybacks represents a strong vote of confidence in Huajian Medical's disruptive experiment in the healthcare sector [9]

华检医疗(01931)公布，于 2025年 7月 10日，该公司子公司威士达医疗设备(上海)有限公司(威士达)(作 为借款人)订立一份可持续发展挂钩银团贷款协议，该协议下威士达获得一项总额达数亿元人民币的循 环贷款，还款期限自首次提款日起为12个月。 本次银团贷款获批数亿元人民币的循环额度，最终获市场热烈反响、实现贷款融资。该循环授信在提款 期内可重复提用，为威士达提供灵活且充裕的中长期资金池，充分彰显国际及区域金融机构对威士达稳 健经营与可持续发展战略的高度认可。 银团贷款协议项下的银团由东亚银行(中国)有限公司上海分行牵头，并由其他银行(贷款人)支持和参 与，贷款人包括三井住友银行(中国)有限公司、日本三井住友信托银行股份有限公司上海分行、盛京银 行股份有限公司上海杨浦支行、韩国釜山银行股份有限公司青岛分行、彰银商业银行有限公司福州分行 及企业银行(中国)有限公司沈阳分行。 ...